31737-09-4 Usage
Description
6-Chloro-1-methyluracil is an organic compound with the molecular formula C5H5ClN2O2. It is a derivative of uracil, a pyrimidine base found in RNA, with a chlorine atom at the 6th position and a methyl group at the 1st position. 6-CHLORO-1-METHYLURACIL is known for its potential applications in the synthesis of various chemical compounds and pharmaceuticals.
Uses
Used in Pharmaceutical Synthesis:
6-Chloro-1-methyluracil is used as a key intermediate in the synthesis of alloxazine 5-oxides and fervenulin 4-oxides. These compounds are of interest in the pharmaceutical industry due to their potential applications in the development of new drugs.
Used in Chemical Research:
In the field of chemical research, 6-chloro-1-methyluracil serves as a valuable starting material for the development of new syntheses and the exploration of novel chemical reactions. Its unique structure allows for further functionalization and modification, leading to the creation of new compounds with potential applications in various industries.
Used in the Synthesis of Alloxazine 5-oxides:
6-Chloro-1-methyluracil is used as a starting material for the synthesis of alloxazine 5-oxides, which are important compounds in the development of pharmaceuticals. The application reason for using this compound in this synthesis is its unique structure, which allows for the formation of the desired alloxazine 5-oxides through nitrative cyclization.
Used in the Synthesis of Fervenulin 4-oxides:
Similarly, 6-chloro-1-methyluracil is also used in the synthesis of fervenulin 4-oxides, another class of compounds with potential pharmaceutical applications. 6-CHLORO-1-METHYLURACIL's structure enables the formation of fervenulin 4-oxides through a similar nitrative cyclization process, making it a valuable intermediate in this synthesis pathway.
Check Digit Verification of cas no
The CAS Registry Mumber 31737-09-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,1,7,3 and 7 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 31737-09:
(7*3)+(6*1)+(5*7)+(4*3)+(3*7)+(2*0)+(1*9)=104
104 % 10 = 4
So 31737-09-4 is a valid CAS Registry Number.
InChI:InChI=1/C5H5ClN2O2/c1-8-3(6)2-4(9)7-5(8)10/h2H,1H3,(H,7,9,10)
31737-09-4Relevant articles and documents
A novel synthesis of fused uracils: Indenopyrimidopyridazines, pyrimidopyridazines, and pyrazolopyrimidines for antimicrobial and antitumor evalution
El-Kalyoubi, Samar,Agili, Fatimah
, (2016)
A variety of different compounds of fused uracils were prepared simply by the heating of 6-hydrazinyl-1-methyl-, 6-hydrazinyl-1-propyl-, or 6-hydrazinyl-1,3-dipropyluracil under reflux with ninhydrin, isatin, benzylidene malononitrile, benzylylidene ethyl cyanoacetate, benzil, and phenacyl bromide derivatives. The newly synthesized compounds were completely screened for antimicrobial and antitumor activity.
Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema
Chen, Xinde,Wang, Kai,Xu, Wenwei,Ma, Quanxin,Chen, Minli,Du, Lili,Mo, Mingguang,Wang, Yiping,Shen, Jianhua
, p. 2674 - 2687 (2016/04/10)
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is considered to be a promising therapeutic target for several inflammation-associated diseases. Herein, we describe the discovery of a series of pyrimidone derivatives as Lp-PLA2 inhibitors. Systematic structural modifications led to the identification of several pyrimidone compounds with promising in vitro inhibitory potency and pharmacokinetic properties. Compound 14c, selected for in vivo evaluation, demonstrated decent pharmacokinetic profiles and robust inhibitory potency against Lp-PLA2 in Sprague-Dawley (SD) rats. Furthermore, 14c significantly inhibited retinal thickening in STZ-induced diabetic SD rats as a model of diabetic macular edema (DME) after oral dosing for 4 weeks. Taken together, these results suggested that 14c can serve as a valuable lead in the search for new Lp-PLA2 inhibitors for prevention and/or treatment of DME.
A mild and efficient method for the deformylation of 5-formyl uracils and synthesis of 4,4￠-methylidenebis(1-phenyl-3-methyl-5-pyrazolone)
Deb, Mohit L.,Majumder, Swarup,Bhuyan, Pulak J.
scheme or table, p. 1982 - 1984 (2010/03/26)
6-Substituted 5-formyl uracils undergo an interesting reaction with 1-phenyl-3-methyl-5-pyrazolone in the presence of base catalyst to afford deformylated uracils and 4,4￠-methylidenebis(1-phenyl-3-methyl-5- pyrazolone) in excellent yields. Georg Thieme V
